Skip to content
NAD Medicinal

A flat, color-blocked readout of the NAD+ literature — what the precursor trials actually measured, where oral NAD+ stops being absorbed, and why most products on the label are NMN or NR rather than NAD+ itself.

NAD+ / STUDIES IN PEOPLE

NAD Clinical Trials: what changed for people?

The human studies were small or short. A few clear findings still held up.

See how NAD+ worksRead the IV findings

What is the plain answer from these trials?

Doctors first wanted to know whether NMN and NR raised NAD+. People were placed into groups by chance. One group got the real pill. Another got a placebo, a pill without the tested ingredient. Blood NAD+ rose with the real pills. A few studies found changes in walking or insulin response. No one proved a longer life. No trial proved that a disease was stopped. That’s the plain answer from the NAD clinical trials.

What happened in the NMN trials?

One small trial followed women past menopause. They had early trouble with blood sugar. The women took 250 mg/day for 10 weeks. Their muscles responded better to insulin [1]. Weight, fat, and lean tissue didn’t change.

A second trial followed healthy adults in middle age. They took 300, 600, or 900 mg/day for 60 days. Blood NAD+ rose on days 30 and 60. People walked farther. They also gave better answers about daily health and how they felt. A blood test meant to estimate the pace of aging didn’t change. The study chose 600 mg/day as the best overall amount [3]. No clear safety problem appeared. People joined at more than one clinic, giving the study a wider mix.

What happened in the NMN trials?

What happened in the NR amount study?

The main NR trial lasted only 8 weeks. It included healthy adults who were overweight. They took 100, 300, or 1000 mg/day. Blood NAD+ rose by 22%, 51%, and 142%. The rise lasted through the study. Flushing wasn’t more common than with the placebo pill [4]. The blood test often called bad cholesterol didn’t rise [4].

Another 14-day trial followed. It tested NR and NMN. Each raised blood NAD+ to about twice the blood NAD+ seen in the placebo group. The placebo pills had neither ingredient. Nicotinamide, a form of niacin, didn’t do that [13]. These blood results don’t prove better health.

What did the smallest illness studies find?

A 2024 review joined 10 trials with 437 people. Their mean age was 58. NMN was tied to faster walking and standing. A 6-minute walk improved too [15]. A questionnaire called SF-36 asked about daily health and how people felt. Its score also improved. The review doesn’t prove every older person will feel better.

The rare-illness work was much smaller. One 52-week NR study followed 9 people with Werner syndrome. That illness makes the body age too soon. Blood NAD+ rose by about 140%. Some heart, cholesterol, and kidney checks improved [11]. Other work ran for 4-month and 2-year periods. It involved ataxia-telangiectasia, an illness that harms balance and movement over time. Movement scores improved or fell more slowly. These small results don’t apply to every illness.

Why did studies keep checking blood NAD+?

Drawing blood is easier than taking tissue from an organ. Most trials therefore checked NAD+ in blood. A higher reading shows that the body used the pill [13]. It can’t show what happened inside the brain or muscle. That gap matters for your health.

The paper prints 22/51/142% beside 100/300/1000 mg/day [4]. Read in order, the smallest amount raised NAD+ by twenty-two percent. The middle amount raised it by fifty-one percent. The largest raised it by one hundred forty-two percent. NMN also raised the reading across 300-900 mg/day [3]. In the 14-day trial, both pills reached about twice the blood NAD+ seen in the placebo group [13]. The blood findings point the same way.

A 2025 review found few checks inside human organs [10]. One fact is firm: blood NAD+ can rise. The health meaning isn’t firm. You can keep both facts in view.

Why did studies keep checking blood NAD+?

What did the human studies fail to prove?

Many trials were small, short, or limited to one illness. They found higher blood NAD+. They didn’t prove longer life or less disease. A 2025 review found few clear health gains in people [10]. It also found little human proof of an age-linked drop. Few studies checked NAD+ inside an organ. Mouse results can’t fill those gaps. For you, a changed blood test isn’t a promised health result.

Did any NAD study check younger looks?

No study here measured how young a person looked. Most strong claims about aging came from mice. A 2025 review called the human results early [10]. The trials didn’t check changes in skin or faces. You can’t draw a beauty claim from this work.